Western Blot (WB)
(Western blot analysis of extracts from HUVEC cells, using NF-kappaB p65 Antibody. The lane on the left was treated withblocking peptide.)
Rabbit NF-kappaB p65 Polyclonal Antibody | anti-RELA antibody
NF-kappaB p65 Antibody
IHC: 1:50-1:200
IF/ICC: 1:200,
ELISA(peptide): 1:20000-1:40000
*The optimal dilutions should be determined by the end user.
IMPORTANT: For western blot, incubate membrane with diluted primary Abin 5% w/v milk , 1X TBS, 0.1% Tween®20 at 4°C with gentle shaking,overnight.
Western Blot (WB)
(Western blot analysis of extracts from HUVEC cells, using NF-kappaB p65 Antibody. The lane on the left was treated withblocking peptide.)
Western Blot (WB)
(Western blot analysis of extracts from HUVEC cells, using NF-kappaB p65 Antibody. The lane on the left was treated withblocking peptide.)
Immunohistochemistry (IHC)
(MBS9601268 at 1/100 staining Human Breast Cancer tissue sections by IHC-P. The tissue was formaldehyde fixed and aheat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary antibody.)
Immunohistochemistry (IHC)
(MBS9601268 at 1/100 staining Human Breast Cancer tissue sections by IHC-P. The tissue was formaldehyde fixed and aheat mediated antigen retrieval step in citrate buffer was performed. The tissue was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary antibody.)
Immunofluorescence (IF)
(MBS9601268 staining HepG2 cells by IF/ICC. The samples werefixed with PFA and permeabilized in 0.1% Triton X-100,thenblocked in 10% serum for 45 minutes at 25°C. Samples were then incubated with primary Ab(MBS9601268) and mouse anti-betatubulin Ab(MBS9610328) for 1 hour at 37°C. An AlexaFluor594conjugated goat anti-rabbit IgG(H+L) Ab(Red) and anAlexaFluor488 conjugated goat anti-mouse IgG(H+L)Ab(Green) were used as the secondary antibody.)
Immunofluorescence (IF)
(MBS9601268 staining HepG2 cells by IF/ICC. The samples werefixed with PFA and permeabilized in 0.1% Triton X-100,thenblocked in 10% serum for 45 minutes at 25°C. Samples were then incubated with primary Ab(MBS9601268) and mouse anti-betatubulin Ab(MBS9610328) for 1 hour at 37°C. An AlexaFluor594conjugated goat anti-rabbit IgG(H+L) Ab(Red) and anAlexaFluor488 conjugated goat anti-mouse IgG(H+L)Ab(Green) were used as the secondary antibody.)
NCBI and Uniprot Product Information
NCBI Description
NF-kappa-B is a ubiquitous transcription factor involved in several biological processes. It is held in the cytoplasm in an inactive state by specific inhibitors. Upon degradation of the inhibitor, NF-kappa-B moves to the nucleus and activates transcription of specific genes. NF-kappa-B is composed of NFKB1 or NFKB2 bound to either REL, RELA, or RELB. The most abundant form of NF-kappa-B is NFKB1 complexed with the product of this gene, RELA. Four transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011]
Uniprot Description
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The heterodimeric RELA-NFKB1 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. The NF-kappa-B heterodimeric RELA-NFKB1 and RELA-REL complexes, for instance, function as transcriptional activators. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The inhibitory effect of I-kappa-B on NF-kappa-B through retention in the cytoplasm is exerted primarily through the interaction with RELA. RELA shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Beside its activity as a direct transcriptional activator, it is also able to modulate promoters accessibility to transcription factors and thereby indirectly regulate gene expression. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells (PubMed:15790681). The NF-kappa-B homodimeric RELA-RELA complex appears to be involved in invasin-mediated activation of IL-8 expression.
Research Articles on RELA
Similar Products
Product Notes
The RELA rela (Catalog #AAA9601268) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The NF-kappaB p65 Antibody reacts with Human, Mouse, Rat, Monkey and may cross-react with other species as described in the data sheet. WB: 1:500-1:2000 IHC: 1:50-1:200 IF/ICC: 1:200, ELISA(peptide): 1:20000-1:40000 *The optimal dilutions should be determined by the end user. IMPORTANT: For western blot, incubate membrane with diluted primary Abin 5% w/v milk, 1X TBS, 0.1% Tween®20 at 4°C with gentle shaking,overnight. Researchers should empirically determine the suitability of the RELA rela for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "NF-kappaB p65, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
